Mr. Pierre A. Caloz is currently the CEO of CSL Behring Bern.

He is also the
Member of Parenteral Drug Association
Member of ISPE
Member of the European Society of Animal Cell Technology (ESACT)
Member of the Swiss Clinical Chemistry Association
Alumni Ashridge and IMD

CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn.

CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited  (ASX:CSL), headquartered in Melbourne, Australia, employs nearly 20’000 people, delivering its life-saving therapies to people in more than 60 countries. For more information visit



Mr. Pierre Caloz is on the Forum Speech Stage